Clozapine use decreases the number of hospitalizations per year in patients with treatment-resistant schizophrenia.

• Autor(a) principal: Londero, Marina Dalla Barba
• Data de Publicação: 2021
• Outros Autores: Hasse-Sousa, Mathias, Petry-Perin, Carolina, Claudino, Felipe Cesar de Almeida, Czepielewski, Letícia Sanguinetti, Gama, Clarissa Severino
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Clinical and Biomedical Research
• Texto Completo: https://seer.ufrgs.br/index.php/hcpa/article/view/105254
• topic: Schizophrenia; Treatment-resistant; Clozapine; Hospitalization

For years, the management of schizophrenia has represented a challenge for clinicians, with antipsychotic treatments usually resulting in relapses and new hospitalizations. Clozapine has been shown to be an effective medication for treatment-resistant schizophrenia (TRS), but is currently underused due to its potential side effects. Nevertheless, research has suggested that clozapine reduces future hospitalizations in patients with TRS. This study aims to verify the rates of hospitalizations in patients with TRS under long-term use of clozapine. We retrospectively analyzed clinical data from 52 individuals with TRS before and after the use of clozapine. The mean duration of treatment with and without clozapine was 6.6 (± 3.9) and 8.5 years (± 6.6), respectively. Patients had a median of 0.5 (0.74) hospitalizations per year before the use of clozapine and 0 (0.74) hospitalizations after it (p = 0.001). Therefore, the use of clozapine resulted in an expected reduction in the number of hospitalizations per year in individuals with TRS.